Abstract
SARS-CoV-2 infection has caused significant morbidity and mortality for both mothers and fetuses, particularly during the Delta variant wave. Identifying high-risk expectant mothers is crucial for preventing adverse outcomes. This retrospective study of 158 patients classified clinical severity based on Society for Maternal-Fetal Medicine (SMFM) guidelines. While 96.2% of patients were in the non-severe group, 3.8% experienced severe infection. Inflammatory markers (CRP, LDH, Ferritin, IL-6, and D-dimer) and the Neutrophil-Lymphocyte Ratio (NLR) were analyzed upon admission. Results showed that CRP, LDH, and Ferritin significantly correlated with disease severity, while IL-6 and D-dimer did not. Notably, an abnormal NLR was present in 100% of severe cases. These findings suggest that simple biomarkers like CRP, LDH, and NLR are sensitive tools for predicting clinical deterioration in pregnant COVID-19 patients.
Introduction
Pregnancy is a high-risk state for respiratory infections due to the physiological and immunological adaptations required to support fetal development. During the COVID-19 pandemic, pregnant women faced elevated risks of critical illness. The primary challenge for clinicians is risk stratification: identifying which patients with a positive PCR test are likely to progress from mild symptoms to respiratory failure. While clinical monitoring remains the gold standard, objective biochemical "early warning systems" are needed to guide triage and intervention, especially in resource-limited settings.
Methods
This retrospective observational study analyzed 158 COVID-19 positive pregnant patients admitted to a tertiary care facility in Coimbatore, India, between March and August 2021. Patients were categorized into five groups (Asymptomatic, Mild, Moderate, Severe, and Critical) per SMFM guidelines. For analysis, these were simplified into "Non-severe" (n=152) and "Severe" (n=6) cohorts. The study evaluated several inflammatory markers collected at admission, including C-Reactive Protein (CRP), Lactate Dehydrogenase (LDH), Ferritin, Interleukin-6 (IL-6), D-dimer, and the Neutrophil-Lymphocyte Ratio (NLR).
Key Results and Statistical Significance
The study found a stark contrast in biomarker levels between the two clinical groups. CRP, LDH, and Ferritin showed highly significant statistical differences (p < 0.01), marking them as reliable indicators of severity. For instance, the mean CRP in the severe group was 11.23 mg/L, compared to 1.65 mg/L in the non-severe group.
Maternal mortality was 1.89% (3/158), with all deaths occurring in the severe group. The stillbirth rate was 3.16%, significantly higher than the pre-pandemic baseline of 0.5%, suggesting direct viral impact on placental health.
The Utility of the Neutrophil-Lymphocyte Ratio (NLR)
One of the most clinically relevant findings was the performance of the NLR. Unlike complex markers like IL-6, which can be expensive and slow to process, NLR is derived from a standard complete blood count. In this cohort, every patient in the severe group (100%) presented with an abnormal NLR (>3) upon admission.
Conversely, D-dimer—a common severity marker in the general population—did not correlate with severity in this study. This is likely due to the natural physiological rise of D-dimer during healthy pregnancy, which masks its utility as a specific marker for COVID-19 progression in expectant mothers.
Conclusion
Inflammatory biomarkers, specifically CRP, LDH, and the NLR, serve as sensitive predictors for adverse maternal and fetal outcomes in COVID-19 positive pregnancies. The NLR, in particular, offers a simple and cost-effective tool with high positive predictive value for identifying patients who require more vigilant monitoring or intensive care. Utilizing these markers upon admission can help clinicians prioritize high-risk patients and improve overall survival rates.
Summary updated